{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:52:06Z","timestamp":1780109526536,"version":"3.54.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.seizure.2021.10.002","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T12:34:29Z","timestamp":1633350869000},"page":"238-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: A study of eight patients"],"prefix":"10.1016","volume":"92","author":[{"given":"Roberto","family":"Caraballo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Reyes","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.seizure.2021.10.002_bib0001","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2021.10.002_bib0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1528-1167.2006.00689.x","article-title":"Cognitive and behavioral outcome in West syndrome","volume":"47","author":"Guzzetta","year":"2006","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2021.10.002_bib0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1535-7511.2006.00100.x","article-title":"Infantile spasms: little seizures, BIG consequences","volume":"6","author":"Shields","year":"2006","journal-title":"Epilepsy Curr"},{"issue":"2","key":"10.1016\/j.seizure.2021.10.002_bib0004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/epi4.12264","article-title":"Treatment of infantile spasms","volume":"3","author":"Hussain","year":"2018","journal-title":"Epilepsia Open"},{"issue":"21","key":"10.1016\/j.seizure.2021.10.002_bib0005","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Cannabidiol in Dravet syndrome study group. Trial of Cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.seizure.2021.10.002_bib0006","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"GWPCARE3 Study Group. Effect of Cannabidiol on drop seizures in the lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"10125","key":"10.1016\/j.seizure.2021.10.002_bib0007","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.seizure.2021.10.002_bib0008","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/epi.14477","article-title":"CBD EAP study group. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results","volume":"59","author":"Szaflarski","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.10.002_bib0009","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.seizure.2021.10.002_bib0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","article-title":"Highly Purified Cannabidiol for epilepsy treatment: a systematic review of epileptic conditions beyond Dravet syndrome and Lennox-Gastaut syndrome","volume":"35","author":"Lattanzi","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2021.10.002_bib0011","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.seizure.2020.06.005","article-title":"Effectiveness of cannabidiol in a prospective cohort of children with drug-resistant epileptic encephalopathy in Argentina","volume":"80","author":"Caraballo","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.10.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106826","article-title":"Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: a multicenter phase-2 study","volume":"102","author":"Hussain","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.seizure.2021.10.002_bib0013","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the international league against epilepsy: position Paper of the ILAE commission for classification and terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.10.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106988","article-title":"Cannabidiol in treatment of refractory epileptic spasms: an open-label study","volume":"106","author":"Herlopian","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.seizure.2021.10.002_bib0015","first-page":"302","article-title":"Brain receptor imaging","volume":"47","author":"Heiss","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.seizure.2021.10.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106446","article-title":"Electroclinical pattern in the transition from West to Lennox-Gastaut syndrome","volume":"167","author":"Calvo","year":"2020","journal-title":"Epilepsy Res"},{"issue":"17","key":"10.1016\/j.seizure.2021.10.002_bib0017","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and safety of Cannabidiol in Epilepsy: a systematic review and meta-analysis","volume":"78","author":"Lattanzi","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.seizure.2021.10.002_bib0018","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/14737175.2021.1834383","article-title":"Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome","volume":"21","author":"Lattanzi","year":"2021","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.seizure.2021.10.002_bib0019","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","article-title":"CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience","volume":"35","author":"Tzadok","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.10.002_bib0020","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.yebeh.2017.01.014","article-title":"Cannabis and epilepsy","volume":"70","author":"Mechoulam","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.seizure.2021.10.002_bib0021","doi-asserted-by":"crossref","first-page":"14948","DOI":"10.1038\/s41598-021-94212-6","article-title":"Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations","volume":"11","author":"Anderson","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.seizure.2021.10.002_bib0022","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fphar.2019.00226","article-title":"Single and Synergistic Effects of Cannabidiol and \u0394-9-Tetrahydrocannabinol on Zebrafish Models of Neuro-Hyperactivity","volume":"10","author":"Samarut","year":"2019","journal-title":"Front Pharmacol"},{"issue":"18","key":"10.1016\/j.seizure.2021.10.002_bib0023","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1111\/bph.15181","article-title":"Interactions between cannabidiol and \u03949 -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome","volume":"177","author":"Anderson","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.seizure.2021.10.002_bib0024","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the Treatment of Epilepsy","volume":"373","author":"Friedman","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121003216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121003216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:01:12Z","timestamp":1761012072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121003216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":24,"alternative-id":["S1059131121003216"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.10.002","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: A study of eight patients","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}